首頁 > 市場調查報告書 > 醫療設備

醫學影像診斷

市場調查報告書

商品編碼

1606515

全球人工智慧醫療影像解決方案市場 - 2024-2031

Global AI-Enabled Medical Imaging Solutions Market - 2024-2031

出版日期: 2024年12月04日 | 出版商:

DataM Intelligence | 英文 176 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

簡介目錄

概述

2023年，全球人工智慧醫療影像解決方案市場規模達到11.2億美元，預計2031年將達到126.4億美元，2024-2031年預測期間複合年成長率為35.6%。

人工智慧醫學影像解決方案是指將人工智慧（AI）技術整合到醫學影像領域，以增強捕捉、分析、解釋和報告診斷影像的過程。這些解決方案利用先進的人工智慧演算法，包括機器學習(ML)、深度學習(DL)、自然語言處理(NLP) 和電腦視覺，來自動化和改進醫學影像工作流程的各個方面，例如影像增強、分割、解釋和決策支援。

由於技術進步、醫療保健需求的增加以及放射學領域對人工智慧的日益偏好，市場對人工智慧醫療成像解決方案的需求正在快速成長。例如，根據北美放射學會的數據，在當前的醫療保健市場中，放射科醫生的人工智慧工具佔據主導地位。在 FDA 批准的 500 多種人工智慧演算法中，有 75% 的目標是放射學實踐，這一比例從 70% 增加。

市場動態：

驅動程式和限制

人口老化加劇

人口老化的加劇正在顯著推動人工智慧醫療成像解決方案市場的成長，預計將在預測期內推動該市場的發展。隨著全球人口老化，癌症、心血管疾病、神經退化性疾病和肌肉骨骼疾病等與年齡相關的疾病的盛行率上升。這些情況需要頻繁監測、早期檢測和準確診斷，而藉助人工智慧成像解決方案可以更有效地實現這些目標。

人工智慧演算法可以幫助放射科醫生更準確、更快速地分析醫學影像，減少人為錯誤並提供更快的診斷。鑑於老年患者通常有多種健康狀況需要立即評估，人工智慧優先考慮、分析和解釋複雜醫學影像的能力對於改善患者治療效果至關重要。

例如，根據世界衛生組織的數據，到 2030 年，全世界每 6 人就有 1 人年齡在 60 歲或以上。此時，60歲及以上人口比例將從2020年的10億增加到14億。到 2050 年，全球 60 歲及以上人口將增加一倍（21 億）。 2020 年至 2050 年間，80 歲及以上的人口數量預計將增加兩倍，達到 4.26 億。

此外，根據 NCOA 研究，近 95% 的 60 歲及以上成年人至少患有一種慢性病，而近 80% 的人患有兩種或兩種以上。而且，根據世界衛生組織的數據，癌症的發生率在生命的後期急劇上升。事實上，到 2022 年，約 53% 的癌症患者年齡在 65 歲或以上。事實證明，人工智慧影像可以有效地早期檢測乳腺癌、肺癌和前列腺癌等癌症，這些癌症在老年人中更為常見。

資料隱私和安全問題

資料隱私和安全問題是阻礙人工智慧醫學影像解決方案市場成長的重大挑戰。這些擔憂主要是由於醫療資料的敏感性、人工智慧系統的複雜性以及針對醫療機構的網路攻擊事件的增加而引起的。

MRI 掃描、CT 掃描和 X 光等醫學影像資料包含高度敏感的個人健康資訊。這些資料通常儲存在基於雲端的系統中或透過網路傳輸以進行人工智慧分析，因此很容易受到未經授權的存取。如果敏感的患者資料遭到洩露，不僅會危及個人隱私，還會損害醫療保健提供者和人工智慧供應商的聲譽，可能導致患者失去信任並減少人工智慧技術的採用。

例如，科羅拉多州的一家病理實驗室正在通知超過180 萬名患者，他們的敏感資訊遭到洩露，這是醫學檢測實驗室向美國聯邦監管機構報告的最大違規行為之一，這使得醫療保健行業特別容易受到駭客的攻擊。

AI-enabled medical imaging solutions refer to the integration of artificial intelligence (AI) technologies into the field of medical imaging to enhance the process of capturing, analyzing, interpreting and reporting diagnostic images. These solutions utilize advanced AI algorithms, including machine learning (ML), deep learning (DL), natural language processing (NLP) and computer vision to automate and improve various aspects of medical imaging workflows, such as image enhancement, segmentation, interpretation and decision support.

The market demand for AI-enabled medical imaging solutions is growing rapidly due to technological advancements, increasing healthcare needs and a growing preference for Artificial Intelligence in radiology. For instance, according to the Radiological Society of North America, in the current healthcare market, AI tools for radiologists dominate. Seventy-five percent of the over 500 FDA-cleared AI algorithms target radiology practice, increasing from 70%.

Market Dynamics: Drivers & Restraints

Rising aging population

The rising aging population is significantly driving the growth of the AI-enabled medical imaging solutions market and is expected to drive the market over the forecast period. As the global population ages, the prevalence of age-related diseases like cancer, cardiovascular conditions, neurodegenerative diseases and musculoskeletal disorders rises. These conditions require frequent monitoring, early detection and accurate diagnosis, which can be achieved more efficiently with AI-enabled imaging solutions.

AI algorithms can assist radiologists in analyzing medical images more accurately and swiftly, reducing human error and providing quicker diagnosis. Given that elderly patients often have multiple health conditions that need to be evaluated at once, AI's ability to prioritize, analyze, and interpret complex medical images is crucial for improving patient outcomes.

For instance, according to the World Health Organization, by 2030, 1 in 6 people in the world will be aged 60 years or over. At this time, the share of the population aged 60 years and over will increase from 1 billion in 2020 to 1.4 billion. By 2050, the world's population of people aged 60 years and older will double (2.1 billion). The number of persons aged 80 years or older is expected to triple between 2020 and 2050 to reach 426 million.

Additionally, According to NCOA research, nearly 95% of adults 60 and older have at least one chronic condition, while nearly 80% have two or more. And, according to the WHO, the incidence of cancer rises dramatically at a later stage in life. In fact, in 2022 about 53% of people who had cancer were 65 or older. AI-powered imaging has proven to be effective in early detection of cancers like breast cancer, lung cancer and prostate cancer conditions that are more prevalent in older adults.

Data privacy and security concerns

Data privacy and security concerns are significant challenges that are hampering the growth of the AI-enabled medical imaging solutions market. These concerns primarily arise due to the sensitive nature of medical data, the complexity of AI systems and the increasing incidents of cyberattacks targeting healthcare organizations.

Medical imaging data, such as MRI scans, CT scans and X-rays, contains highly sensitive personal health information. This data is often stored in cloud-based systems or transmitted over networks for AI analysis, making it vulnerable to unauthorized access. If sensitive patient data is compromised, it not only jeopardizes individual privacy but also damages the reputation of healthcare providers and AI vendors, potentially leading to loss of patient trust and reduced adoption of AI technologies.

For instance, a Colorado-based pathology laboratory is notifying more than 1.8 million patients that their sensitive information was compromised one of the largest breaches reported by a medical testing lab to US federal regulators, making the healthcare industry especially vulnerable to hackers.

Segment Analysis

The global AI-enabled medical imaging solutions market is segmented based on imaging modality, deployment mode, application, end-user and region.

Application:

The oncology segment is expected to dominate the global AI-enabled medical imaging solutions market share

The oncology segment holds a major portion of the AI-enabled medical imaging solutions market share and is expected to continue to hold a significant portion of the market share over the forecast period. his dominance is primarily driven by the critical need for early cancer detection, improved diagnostic accuracy and the growing adoption of AI technologies in oncology diagnostics.

Cancer is one of the leading causes of death worldwide. According to the World Health Organization (WHO), nearly 10 million people die from cancer each year. As cancer rates increase globally, the demand for effective diagnostic tools, including AI-powered medical imaging solutions, rises.

Early detection is crucial in improving cancer survival rates. AI has shown its potential to enhance the accuracy and speed of detecting cancers at an early stage. AI-enabled imaging solutions can analyze medical images (such as CT scans, MRIs, and mammograms) for early signs of cancer, enabling more effective and timely treatment.

For instance, the Harvard University team tested the AI tool, CHIEF (Clinical Histopathology Imaging Evaluation Foundation) performance on more than 19,400 whole-slide images from 32 independent datasets collected from 24 hospitals and patient cohorts across the globe. CHIEF achieved nearly 94 percent accuracy in cancer detection and significantly outperformed current AI approaches across 15 datasets containing 11 cancer types.

North America is expected to hold a significant position in the global AI-enabled medical imaging solutions market

North America region is expected to hold the largest market share over the forecast period. North America, particularly the United States and Canada, has some of the most advanced healthcare systems globally. These systems have the infrastructure and resources needed to implement and scale AI-driven medical imaging solutions.

For instance, the U.S. healthcare market is one of the largest in the world, with healthcare spending grew 4.1 percent in 2022, reaching $4.5 trillion or $13,493 per person, according to the Centers for Medicare & Medicaid Services (CMS). This substantial investment supports the adoption of cutting-edge technologies like AI in medical imaging to improve diagnostic accuracy and efficiency.

North America especially in the United States, is a global leader in artificial intelligence innovation, with tech giants heavily involved in the development of AI technologies for healthcare applications, including medical imaging. For instance, in April 2023, Exo cleared its FDA-cleared cardiac and lung artificial intelligence (AI) applications are available on Exo Iris, Exo's high-performance handheld ultrasound device. With affordable, AI-powered medical imaging in a pocket-sized device, caregivers can get answers immediately to accelerate diagnosis and create new care pathways for heart failure patients at the point of care.

Asia Pacific is growing at the fastest pace in the AI-enabled medical imaging solutions market

The Asia Pacific region is experiencing the fastest growth in the AI-enabled medical imaging solutions market. The Asia Pacific region is home to 60% of the world's population, with over 4.3 billion people. This large and diverse population presents a significant demand for healthcare services, including advanced diagnostic solutions like AI-powered medical imaging. As the population grows, so does the prevalence of health conditions such as cancer, cardiovascular diseases and neurological disorders, driving the demand for AI-powered diagnostic tools to help healthcare providers manage these conditions more effectively.

For instance, China and India, with populations over 1.4 billion and 1.4 billion respectively, are seeing a rise in diseases like lung cancer and diabetes, which are major drivers for the adoption of AI medical imaging tools in early detection and diagnosis.

Asia-Pacific countries are seeing a significant rise in chronic diseases, such as cancer, cardiovascular diseases and diabetes, necessitating the adoption of advanced diagnostic tools like AI-driven imaging to detect these diseases in their early stages. For instance, India has seen a rising incidence of cancer, with the Indian Council of Medical Research (ICMR) estimating that cancer cases will increase by more than 25% by 2035, highlighting the demand for AI-enabled imaging solutions for early diagnosis.

Competitive Landscape

The major global players in the AI-enabled medical imaging solutions market include deepc GmbH, Qure.ai Technologies Private Limited, DeepTek.ai, Inc, Aidoc, Tempus AI, Inc., Rayscape, Infervision, AIKENIST, Rad AI, Brainomix Limited and among others.

Why Purchase the Report?

Pipeline & Innovations: Reviews ongoing clinical trials, product pipelines, and forecasts upcoming advancements in medical devices and pharmaceuticals.
Product Performance & Market Positioning: Analyzes product performance, market positioning, and growth potential to optimize strategies.
Real-World Evidence: Integrates patient feedback and data into product development for improved outcomes.
Physician Preferences & Health System Impact: Examines healthcare provider behaviors and the impact of health system mergers on adoption strategies.
Market Updates & Industry Changes: Covers recent regulatory changes, new policies, and emerging technologies.
Competitive Strategies: Analyzes competitor strategies, market share, and emerging players.
Pricing & Market Access: Reviews pricing models, reimbursement trends, and market access strategies.
Market Entry & Expansion: Identifies optimal strategies for entering new markets and partnerships.
Regional Growth & Investment: Highlights high-growth regions and investment opportunities.
Supply Chain Optimization: Assesses supply chain risks and distribution strategies for efficient product delivery.
Sustainability & Regulatory Impact: Focuses on eco-friendly practices and evolving regulations in healthcare.
Post-market Surveillance: Uses post-market data to enhance product safety and access.
Pharmacoeconomics & Value-Based Pricing: Analyzes the shift to value-based pricing and data-driven decision-making in R&D.

The global artificial organs and bionics market report delivers a detailed analysis with 60+ key tables, more than 50 visually impactful figures, and 176 pages of expert insights, providing a complete view of the market landscape.

Target Audience 2023

Manufacturers: Pharmaceutical, Medical Device, Biotech Companies, Contract Manufacturers, Distributors, Hospitals.
Regulatory & Policy: Compliance Officers, Government, Health Economists, Market Access Specialists.
Technology & Innovation: AI/Robotics Providers, R&D Professionals, Clinical Trial Managers, Pharmacovigilance Experts.
Investors: Healthcare Investors, Venture Fund Investors, Pharma Marketing & Sales.
Consulting & Advisory: Healthcare Consultants, Industry Associations, Analysts.
Supply Chain: Distribution and Supply Chain Managers.
Consumers & Advocacy: Patients, Advocacy Groups, Insurance Companies.
Academic & Research: Academic Institutions.

1. Methodology and Scope

1.1. Research Methodology
1.2. Research Objective and Scope of the Report

2. Definition and Overview

3. Executive Summary

3.1. Snippet by Imaging Modality
3.2. Snippet by Deployment Mode
3.3. Snippet by Application
3.4. Snippet by End-User
3.5. Snippet by Region

4. Dynamics

4.1. Impacting Factors
- 4.1.1. Drivers
  - 4.1.1.1. Rising Aging Population
  - 4.1.1.2. Rapid Analysis and Decision Making
- 4.1.2. Restraints
  - 4.1.2.1. Data Privacy and Security Concerns
- 4.1.3. Opportunity
- 4.1.4. Impact Analysis

5. Industry Analysis

5.1. Porter's Five Force Analysis
5.2. Supply Chain Analysis
5.3. Pricing Analysis
5.4. Patent Analysis
5.5. Regulatory Analysis
5.6. SWOT Analysis
5.7. Unmet Needs

6. By Imaging Modality

6.1. Introduction
- 6.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Imaging Modality
- 6.1.2. Market Attractiveness Index, By Imaging Modality
6.2. X-ray Imaging*
- 6.2.1. Introduction
- 6.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
6.3. Magnetic Resonance Imaging (MRI)
6.4. Computed Tomography (CT)
6.5. Ultrasound Imaging
6.6. Mammography
6.7. Others

7. By Deployment Mode

7.1. Introduction
- 7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Deployment Mode
- 7.1.2. Market Attractiveness Index, By Deployment Mode
7.2. Cloud-Based Solutions*
- 7.2.1. Introduction
- 7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
7.3. On-Premise Solutions
7.4. Hybrid Models

8. By Application

8.1. Introduction
- 8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
- 8.1.2. Market Attractiveness Index, By Application
8.2. Oncology*
- 8.2.1. Introduction
- 8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
8.3. Cardiology
8.4. Neurology
8.5. Respiratory Disorders
8.6. Orthopedics
8.7. Gastroenterology
8.8. Others

9. By End-User

9.1. Introduction
- 9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
- 9.1.2. Market Attractiveness Index, By End-User
9.2. Hospitals*
- 9.2.1. Introduction
- 9.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
9.3. Diagnostic Centers
9.4. Specialty Clinics
9.5. Academic and Research Institutes

10. By Region

10.1. Introduction
- 10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
- 10.1.2. Market Attractiveness Index, By Region
10.2. North America
- 10.2.1. Introduction
- 10.2.2. Key Region-Specific Dynamics
- 10.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Imaging Modality
- 10.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Deployment Mode
- 10.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
- 10.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
- 10.2.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
  - 10.2.7.1. U.S.
  - 10.2.7.2. Canada
  - 10.2.7.3. Mexico
10.3. Europe
- 10.3.1. Introduction
- 10.3.2. Key Region-Specific Dynamics
- 10.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Imaging Modality
- 10.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Deployment Mode
- 10.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
- 10.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
- 10.3.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
  - 10.3.7.1. Germany
  - 10.3.7.2. U.K.
  - 10.3.7.3. France
  - 10.3.7.4. Spain
  - 10.3.7.5. Italy
  - 10.3.7.6. Rest of Europe
10.4. South America
- 10.4.1. Introduction
- 10.4.2. Key Region-Specific Dynamics
- 10.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Imaging Modality
- 10.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Deployment Mode
- 10.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
- 10.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
- 10.4.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
  - 10.4.7.1. Brazil
  - 10.4.7.2. Argentina
  - 10.4.7.3. Rest of South America
10.5. Asia-Pacific
- 10.5.1. Introduction
- 10.5.2. Key Region-Specific Dynamics
- 10.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Imaging Modality
- 10.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Deployment Mode
- 10.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
- 10.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
- 10.5.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
  - 10.5.7.1. China
  - 10.5.7.2. India
  - 10.5.7.3. Japan
  - 10.5.7.4. South Korea
  - 10.5.7.5. Rest of Asia-Pacific
10.6. Middle East and Africa
- 10.6.1. Introduction
- 10.6.2. Key Region-Specific Dynamics
- 10.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Imaging Modality
- 10.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Deployment Mode
- 10.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
- 10.6.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User

11. Competitive Landscape

11.1. Competitive Scenario
11.2. Market Positioning/Share Analysis
11.3. Mergers and Acquisitions Analysis

12. Company Profiles

12.1. deepc GmbH*
- 12.1.1. Company Overview
- 12.1.2. Product Portfolio and Description
- 12.1.3. Financial Overview
- 12.1.4. Key Developments
12.2. Qure.ai Technologies Private Limited
12.3. DeepTek.ai, Inc
12.4. Aidoc
12.5. Tempus AI, Inc.
12.6. Rayscape
12.7. Infervision
12.8. AIKENIST
12.9. Rad AI
12.10. Brainomix Limited

LIST NOT EXHAUSTIVE